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Healthy first-degree relatives of pediatric inflammatory
bowel disease patients can have a fecal microbial and
metabolomics profile seen in many patients with quiescent
inflammatory bowel disease. This potential predisease state
was associated with an increased likelihood of increased
fecal calprotectin levels.
BACKGROUND & AIMS: Microbes may increase susceptibility
to inflammatory bowel disease (IBD) by producing bioactive
metabolites that affect immune activity and epithelial function.
We undertook a family based study to identify microbial and
metabolic features of IBD that may represent a predisease risk
state when found in healthy first-degree relatives.
METHODS: Twenty-one families with pediatric IBD were
recruited, comprising 26 Crohn’s disease patients in clinical
remission, 10 ulcerative colitis patients in clinical remission,
and 54 healthy siblings/parents. Fecal samples were collected
for 16S ribosomal RNA gene sequencing, untargeted liquid
chromatography–mass spectrometry metabolomics, and cal-
protectin measurement. Individuals were grouped into micro-
bial and metabolomics states using Dirichlet multinomial
models. Multivariate models were used to identify microbes
and metabolites associated with these states.
RESULTS: Individuals were classified into 2 microbial com-
munity types. One was associated with IBD but irrespective of
disease status, had lower microbial diversity, and characteristic
shifts in microbial composition including increased Enter-
obacteriaceae, consistent with dysbiosis. This microbial com-
munity type was associated similarly with IBD and reduced
microbial diversity in an independent pediatric cohort. In-
dividuals also clustered bioinformatically into 2 subsets with
shared fecal metabolomics signatures. One metabotype was
associated with IBD and was characterized by increased bile
acids, taurine, and tryptophan. The IBD-associated microbial
and metabolomics states were highly correlated, suggesting
that they represented an integrated ecosystem. Healthy rela-
tives with the IBD-associated microbial community type had an
increased incidence of elevated fecal calprotectin.CONCLUSIONS: Healthy first-degree relatives can have dys-
biosis associated with an altered intestinal metabolome that
may signify a predisease microbial susceptibility state or sub-
clinical inflammation. Longitudinal prospective studies are
required to determine whether these individuals have a clini-
cally significant increased risk for developing IBD. (Cell Mol
Gastroenterol Hepatol 2016;2:750–766; http://dx.doi.org/
10.1016/j.jcmgh.2016.06.004)
Keywords: Microbiome; Metabolomics; Inflammatory Bowel
Disease; Family Cohort.
he inflammatory bowel diseases (IBDs)—Tcomprising Crohn’s disease (CD) and ulcerative
colitis (UC)—are chronic inflammatory diseases with a
growing prevalence worldwide.1 IBD is believed to arise
from a combination of genetic susceptibility and environ-
mental factors that trigger an inappropriate mucosal in-
flammatory response.2 A pathogenic role for the intestinal
microbiome at the junction of genetics and environment is
supported by the resistance of germ-free mice to experi-
mental colitis models and the transmissibility of colitis by
microbiota derived from mice with genetic defects in
mucosal immunity.3–5 IBD patients have reduced microbial
diversity and alterations in the composition and function of
the intestinal microbiome compared with healthy con-
trols.6–10 Founder effects and diet are important environ-
mental factors in microbial composition, and are associated
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pothesis that IBD involves a dysbiosis arising from a com-
bination of environmental and genetic perturbations of the
mucosal habitat controlling microbial composition.12,13
It remains unclear which differentially abundant mi-
crobes in IBD patients are instigators of disease rather than
bystanders responding to the altered environment of the
inflamed intestine. An important prospect for resolution is
the expanding recognition of bioactive microbial products
that profoundly can affect mucosal immune responses and
epithelial homeostasis.14 For instance, IBD patients have
reduced fecal concentrations of short-chain fatty acids such
as butyrate that limit inflammatory responses in colitis
models.15–17 This may be attributable to shifts in the
microbiome including reduced abundance of the prominent
butyrate-producer Faecalibacterium prausnitzii.8,9,18
Administration of F prausnitzii or its culture supernatant
ameliorated experimental colitis; however, treatment of
mice with butyrate at the concentration in culture super-
natant did not affect colitis severity.18 This underscores the
need to more fully characterize the IBD-associated metab-
olome and the scope of microbial products relevant to dis-
ease pathogenesis.
If IBD develops as a consequence of a host response to a
proinflammatory microbiome and its associated microbial
products, as has been reported in animal models, IBD pa-
tients would be predicted to have harbored dysbiosis before
the development of disease. We performed a family-based
study of the microbiome and metabolome of pediatric IBD
patients and their unaffected first-degree relatives, who are
at heightened risk for developing IBD. We hypothesized that
unaffected siblings and parents—previously reported to
have increased fecal calprotectin levels compared with
healthy unrelated controls—may carry a predisease micro-
bial risk state owing to shared genetic and environmental
factors with the IBD proband.19,20 We found that individuals
in the family cohort grouped into 1 of 2 states based on fecal
microbial and metabolomics profiles, which could be defined
bioinformatically as OTU types and metabotypes (multidi-
mensional community clusters characterized by differences
in the abundance of signature taxa or metabolites, respec-
tively).21 These OTU types and metabotypes were correlated
highly with one another, and with disease status. We propose
that in families at risk for IBD, a subset of healthy individuals
harbor a stable intestinal microbial/metabolomic state that
may confer increased susceptibility to IBD.Materials and Methods
Cohort Recruitment and Sample Collection
Twenty-one CD and UC probands younger than the age
of 18 were recruited from the Pediatric IBD Center at the
Cedars-Sinai Medical Center. All patients were in clinical
remission at the time of collection as evidenced by a
Harvey–Bradshaw Index score of less than 5 for CD patients
or a partial Mayo score of less than 2 for UC patients. Family
members of these probands were recruited and assessed by
detailed questionnaire for history of IBD. Six siblings and 9
parents were known to have IBD. Non-IBD family memberswere validated by lack of symptoms or medications sug-
gestive of undiagnosed IBD. Participants were provided
with a toilet hat, sample containers, and cold packs for home
collection. Freshly defecated feces were frozen immediately
at the clinic or at home and then brought to the clinic on
cold packs for storage at -80C. Frozen fecal samples were
ground with a mortar and pestle in the presence of liquid
nitrogen and then aliquoted for microbiome and metab-
olome analysis. Fecal calprotectin was measured from
frozen aliquots of stool by an enzyme-linked immunosor-
bent assay performed by Quest Diagnostics (Los Angeles,
CA). This research was approved by the Cedars-Sinai Med-
ical Center Institutional Review Board under IRB 3766. All
authors had access to the study data and reviewed and
approved the final manuscript.16S Ribosomal RNA Gene Sequencing
Genomic DNA was extracted using the PowerSoil DNA
Isolation Kit (MO BIO Laboratories, Carlsbad, CA) with a 30-
second, beat-beating step using a Mini-Beadbeater-16
(BioSpec Products, Bartlesville, OK).22 Polymerase chain
reaction amplification of bacterial 16S ribosomal RNA
(rRNA) genes was performed using extracted genomic DNA
as the template. The 100-mL reactions contained 50 mmol/
L Tris (pH 8.3), 500 mg/mL bovine serum albumin, 2.5
mmol/L MgCl2, 250 mmol/L of each of the 4 deoxynucleo-
tide triphosphates, 400 nmol/L of each primer, 4 mL of DNA
template, and 2.5 U JumpStart Taq DNA polymerase (Sigma-
Aldrich, St. Louis, MO). The polymerase chain reaction
(PCR) primers (F515/R806) targeted the V4 hypervariable
region of the 16S rRNA gene, with the reverse primers
including a 12-bp Golay barcode.23 Thermal cycling was
performed in an MJ Research PTC-200 (Bio-Rad, Inc, Her-
cules, CA) with the following parameters: 94C for 5 mi-
nutes; 35 cycles of 94C for 20 seconds, 50C for 20
seconds, and 72C for 30 seconds; and 72C for 5 minutes.
PCR products were purified using the MinElute 96 UF PCR
Purification Kit (Qiagen, Valencia, CA). DNA sequencing was
performed using an Illumina HiSeq 2000 (Illumina, Inc, San
Diego, CA). Clusters were created using template concen-
trations of 1.9 pmol/L and PhiX at 65 K/mm2. Sequencing
primers targeted 101 base pair reads of the 5’ end of the
amplicons and 7 base pair barcode reads.23 Reads were
filtered using the following parameters: minimum Q-score, -
20; maximum number of consecutive low-quality base calls
allowed before truncating, - 3; and maximum number of N
characters allowed, - 0. All filtered V4 reads had a length of
101 bp. The number of sequences per sample ranged from
17,946 (an outlier; the second lowest sequence depth was
478,168) to 848,638, with a mean of 620,720. Raw 16S
rRNA sequence data were deposited under National Center
for Biotechnology Information BioProject ID PRJNA324147.
Operational taxonomic units (OTUs) were picked in QIIME
1.8.0 against the May 2013 version of the Greengenes
database (http://greengenes.secondgenome.com), prefil-
tered at 97% identity.24 The number of reads assigned to
97% OTUs ranged from 445,985 to 805,639, excluding the
lowest depth sample (16,941).
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leaving 7967 OTUs. a Diversity was assessed in QIIME using
Faith’s phylogenetic diversity, Chao1, and the Shannon index
with data rarefied to 445,975 sequences. Statistical signifi-
cance was assessed using the Mann–Whitney U test. b Di-
versity was assessed on unrarefied data using the square
root of the Jensen–Shannon divergence (calculated in R with
a script available at http://enterotype.embl.de/enterotypes.
html) and on data rarefied to 445,975 sequences using
Bray–Curtis and unweighted UniFrac (calculated in QIIME).
Principal coordinates analysis was used to visualize b di-
versity. Adonis with 100,000 permutations was used to
assess statistical significance of differences in b diversity.25Ultra-Performance Liquid Chromatography/
Time-of-Flight Mass Spectrometry
Untargeted Metabolomics
A total of 50 mg of each fecal sample was dried, resus-
pended in 150 mL of Optima liquid chromatography/mass
spectrometry (LC/MS) grade water on ice, subjected to heat
shock in a 37C water bath for 90 seconds, then chilled on
ice. One microliter from each sample was removed for
protein concentration measurement. Six hundred microli-
ters of chilled methanol containing internal standards for
lipidomics and metabolomics was added to each sample and
incubated on ice for 15 minutes as previously described.26
An equal volume of chloroform then was added to the
mixture. The samples then were centrifuged at 16,000g for
10 minutes. The organic and aqueous phases were sepa-
rated carefully, followed by addition of 600 mL of chilled
acetonitrile for overnight incubation at -20C. The samples
then were centrifuged at maximum speed at room temper-
ature for 10 minutes. Supernatants were combined and
transferred to new glass tubes, dried under a gentle stream
of N2, and resuspended in 100 mL of solvent A for LC/MS.
The MS analysis was performed by injecting 2-mL ali-
quots of each sample into a reverse-phase 50  2.1 mm
H-class Ultra-Performance Liquid Chromatography (UPLC)
Acquity 1.7-mmol/L BEH C18 column (Waters Corp, Milford,
MA, USA), coupled to a time of flight mass spectrometry
(ToFMS). The mobile phase consisted of water and 0.1%
formic acid (solvent A), 100% acetonitrile (solvent B), and
isopropanol/acetonitrile (90:10, vol:vol) with 10 mmol/L
ammonium formate (solvent C). The Xevo G2-S mass spec-
trometer (Waters Corp) was operated in the positive (ESIþ)
and negative (ESI-) electrospray ionization modes scanning
a 50- to 1200-m/z range. The following 13-minute gradient
was used: 95%/5% solvent A/solvent B at 0.45 mL/min for
8 minutes, 2%/98% solvent A/solvent B for 1 minute, 2%/
98% solvent B/solvent C for 1.5 minutes, 50%/50% solvent
A/solvent B for 1.5 minutes, and 95%/5% solvent A/solvent
B for the remaining half a minute. The lock-spray consisted
of leucine-enkephalin (556.2771 [MþH]þ and 554.2615
[M-H]-). The MS data were acquired in centroid mode and
processed using MassLynx software (Waters Corp) to
construct a data matrix consisting of the retention time,
m/z, and intensity (via the peak area normalized to protein
concentration) for each ion. A total of 3206 ions weredetected in the positive mode and 1420 ions were detected
in the negative mode.
Our in-house statistical analysis program was used to
putatively identify ions, using the Human Metabolome
Database, LipidMaps, the Kyoto Encyclopedia of Genes and
Genomes database, and BioCyc. The m/z values were used
to putatively assign IDs to the ions by neutral mass eluci-
dation, which was accomplished by considering the possible
adducts (Hþ, Naþ, and/or NH4
þ in the ESIþ mode; and H-
and Cl- in the ESI- mode). The masses then were compared
with the exact mass of small molecules in the databases,
from which putative metabolites were identified with a
mass error of 20 ppm or less. MS/MS validation was per-
formed by comparing the fragmentation pattern of each
metabolite and lipid of interest against either that of its pure
chemical form or its published MS/MS spectra in Metlin or
our in-house database.27 Validation was performed for 123
spectral features, of which 37 were validated successfully.
Community-Type Analysis
Individuals were grouped into OTU types and metab-
otypes by applying Dirichlet multinomial mixture models to
16S sequence data and UPLC-ToFMS metabolomics data.28
This approach has been reported to outperform partition-
ing around medoids for clustering individuals by their
microbiome in simulation studies and using Human Micro-
biome Project data.29 Modeling was performed using the
get.communitytype function in Mothur v.1.36.1 with default
parameters for the minimum (5) and maximum (10) num-
ber of partitions tested.30 Model fit for each possible num-
ber of OTU types or metabotypes was estimated using the
Laplace approximation. The exponent of the difference in
model fit serves as an estimate of the probability of one
model over another.
Differential Abundance Testing
Nonrarefied 16S rRNA sequence data and UPLC-ToFMS
metabolomics data were filtered to remove OTUs and
spectral features present in less than 10% of samples. The
sample with 17,946 16S rRNA sequences was excluded. The
resulting filtered data sets were analyzed using DESeq2
(http://www.bioconductor.org/packages/release/bioc/html/
DESeq2.html). This algorithm performs normalization using
size factors estimated by the median-of-ratios method, uses
an empiric Bayesian approach to shrink dispersion, and fits
the data to negative binomial models.31 Covariates included
sex, Jewish ancestry, current anti–tumor necrosis factor
therapy, mode of delivery, family group, IBD diagnosis, and
OTU type/metabotype. P values for variables in the linear
models (eg, IBD status) were converted to q values to cor-
rect for multiple hypothesis testing. This was implemented
with the R script q value (https://github.com/jdstorey/
qvalue), which for each P value estimates the false-
discovery rate based on the distribution of P values.32
Q values less than 0.05 were considered significant. Hier-
archical clustering of metabolite abundance data and visu-
alization with heat maps were performed in GENE-E
(http://www.broadinstitute.org/cancer/software/GENE-E).
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coefficient with the average linkage method.
Random Forest Classifiers
Random forest classifiers to predict OTU type,
metabotype, and CD were created in R using the random-
Forest package (https://cran.r-project.org/web/packages/
randomForest) with 1001 trees and mtry ¼ 2.33 Fea-
tures were inputted into the algorithm if they were
associated significantly with the trait in multivariate
DESeq2 models and were present in at least 30% of sam-
ples. The accuracy of random forest classifiers was esti-
mated using 10-fold cross-validation. The OTU-type
classifier trained on the family cohort was used to predict
the OTU type of fecal samples in the RISK cohort (a previ-
ously published pediatric Crohn’s disease inception
cohort).9 Subjects with recent exposure to antibiotics were
excluded. The RISK cohort data were kindly supplied by the
authors of that study (Gevers and Huttenhower) as a count
table of 97% OTUs picked against the Greengenes database
of OTUs, allowing for matching of OTUs with those in the
random forest classifier. The OTU-type classifier was con-
structed from 57 OTUs that were differentially abundant by
OTU type (as visualized in Figure 1E), present in at least
30% of samples in the family cohort, and present in at least
30% of samples in the RISK cohort after both data sets were
rarefied to 20,000 sequences/samples to adjust for different
sequence depths.9
Inter’omic Analysis
Similarity between the microbiome and metabolomics
data sets was assessed by Procrustes superimposition of
principal coordinates constructed from distance matrices
calculated using the square root of the Jensen–Shannon
divergence.34 Significance of the Procrustes analysis was
determined using 10,000 Monte Carlo permutations in
QIIME. An inter’omic network was constructed in Cytoscape
3.2.1 (http://cytoscape.org) from OTUs and spectral fea-
tures that had a random forest importance score greater
than 2 in classifiers for OTU type and metabotype.
Spearman correlations were calculated for all OTU–OTU,
metabolite–metabolite, and OTU–metabolite pairs using the
residuals of DESeq2 multivariate models incorporating IBD
status, OTU type or metabotype, sex, current anti–tumor
necrosis factor therapy, Jewish ethnicity, mode of delivery,
and family. P values were computed for Spearman correla-
tion coefficients based on the asymptotic t approximation
and then were converted to q values in R. Correlation pairs
with a q value less than 0.05 represented edges in the
network.
Logistic Regression
Multivariate and univariate logistic regression were
performed in R using the glm function. Multivariate models
for IBD that included parent/child status and Jewish
ethnicity had improved fit by the likelihood ratio test rela-
tive to models without these covariates.Results
A Low-Diversity IBD-Associated Microbial
Community Type Is Present In Healthy
First-Degree Relatives of Pediatric IBD Patients
We recruited a cohort of 21 families with pediatric IBD,
consisting of 36 IBD patients (21 probands, 6 siblings, and 9
parents) and 54 healthy first-degree relatives (Table 1). The
IBD subjects included 26 with CD and 10 with UC. All were
in clinical remission to reduce confounding of microbial and
metabolomics analyses by the effects of active disease.
Twenty of 22 of the probands and their siblings with CD had
small intestinal involvement; of these, 14 also had colonic
involvement. All but 5 of the IBD subjects were on medi-
cation, including 21 on a tumor necrosis factor inhibitor
(with or without immunomodulators; ie, methotrexate or 6-
mercaptopurine), 2 exclusively on an immunomodulator,
and 9 on mesalamine therapy. The probands and their sib-
lings underwent an extensive characterization of their
neonatal and early life medical history. No differences were
seen between children with IBD and their healthy siblings in
mode of delivery (vaginal vs Cesarean), birth order, gesta-
tional age, birth weight, perinatal disease, maternal antibi-
otic use predelivery, maternal age, and early life antibiotic
treatment. The cohort was predominantly of European
ancestry, with the majority self-identifying as Jewish (60
individuals). Two parents were of non-European ancestry (1
Asian, 1 Hispanic), accounting for 4 mixed-race children in
the cohort.
High-depth 16S rRNA sequencing was performed on
fecal samples (mean, 620,720 reads per sample) to detect
low-abundance taxa that may be critical for IBD suscepti-
bility. Consistent with previous studies, CD patients had
lower microbial diversity than both UC patients and
healthy individuals as measured by 3 metrics: Chao1
(richness), Faith’s phylogenetic diversity, and the Shannon
index (evenness) (CD vs non-IBD, P < .0001 for all mea-
sures; CD vs UC, P < .05–.005). Differences in microbial
composition across samples were visualized using prin-
cipal coordinate analysis (PCoA). Samples formed a
gradient by IBD status and microbial diversity, both of
which were highly significantly associated with overall
composition using Adonis, a nonparametric method of
analysis of variance (Figure 1A). These findings were
confirmed using Bray–Curtis or unweighted UniFrac dis-
tances (data not shown). CD patients and healthy relatives
mostly occupied distinct regions of the PCoA space but had
substantial overlap; UC patients were interspersed
throughout. A subset of Crohn’s patients in this cohort had
increased fecal calprotectin levels to greater than 2000 mg/
g despite being in clinical remission, but calprotectin was
not associated with overall microbial composition. Micro-
bial composition was found to vary across families (Adonis,
P < 10-5) (Figure 2A and B).
It has been reported that the human fecal microbiome
can be divided into discrete community types.21,29 To
investigate whether variation in microbial composition in
this cohort could be represented by microbial community
types, we classified individuals using a conservative,
Figure 1. A low-diversity microbial community type is associated with IBD but also is present in healthy relatives. (A)
PCoA plots were used to visualize differences in microbial composition across samples (b diversity) as measured by the
square root of the Jensen–Shannon divergence. Dots represent fecal samples colored by IBD status (left 2 panels), Chao1 (a
measure of microbial richness), or OTU type (determined using Dirichlet multinomial mixture models). Dot size corresponds to
fecal calprotectin level in the second panel from the left. P values for the association of the indicated variable (IBD status,
calprotectin, Chao1, and OTU type) with microbial composition were calculated using Adonis. (B) Contingency table of IBD
status by OTU type. P value was calculated using the Fisher exact test. (C) Chao1 by IBD status and OTU type. P values were
calculated using the Mann–Whitney U test. *P < .05, **P < .005, ***P < .0001. (D) Venn diagram indicating differential OTUs for
CD (vs non-IBD), UC (vs non-IBD), and OTU type (2 vs 1) in multivariate DESeq2 models including sex, Jewish ancestry,
current anti–tumor necrosis factor therapy, mode of delivery, family group, IBD diagnosis, and OTU type as covariates. (E)
OTUs with a statistically significant difference in abundance between OTU types 2 and 1 in multivariate DESeq2 models are
shown. Effect size is represented as the log2 fold-change (FC) between OTU types 2 and 1. Dot size is proportional to the
abundance of that OTU after normalization in DESeq2. Only OTUs with a mean normalized abundance greater than 10-4 are
included. Color signifies whether the OTU also is differentially abundant in CD, UC, or both. The genus of each OTU is shown
on the horizontal axis, ordered by the log2 FC between OTU types 2 and 1 of the genus as a whole. OTUs are grouped into
families (f) where indicated if they did not have an assigned genus. OTUs putatively identified at the species level in the
Greengenes database are annotated.
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Table 1.Cohort Demographics
Probands
Siblings
with IBD
Healthy
siblings Parents
N 21 6 21 42
Crohn’s disease 17 5 4
Ulcerative colitis 4 1 5
Sex
Male 14 5 10 21
Female 7 1 11 21
Race/ethnicity
Caucasian 19 6 19
Jewish 13 4 15
Mixed 2 0 2
Age at diagnosis, y 10 18.4
Age at sampling, y 13.6 19.7 12.7
Crohn’s disease
location
Small intestine 15 5
Colon
involvement
10 4
UGI
involvement
6 1
Perianal
disease
7 1
Colon only 2 0
IBD medications at
sampling
Anti-TNF 16 3 2
Methotrexatea 10 1 0
6-MP/
azathioprinea
2 0 0
Mesalamine 6 1 2
None 1 1 3
Birth order 1.7 1.3 1.9
Mode of delivery
Vaginal 16 4 15
Cesarean 5 2 6
Gestational age,
wkb
0.2 0.3 0.0
Birth weight, lb 7.4 6.8 7.0
Perinatal disease 8 2 3
Anemia 3 0 1
Preterm labor 1 2 0
Preeclampsia 1 0 0
Other 3 0 2
Antibiotics
predelivery
3 1 3
Maternal age at
delivery, y
33.9 32 33.4
Exclusive
breastfeedingc
20 4 17
2 antibiotics
during first year
4 1 4
NOTE. There were no statistically significant differences in
metadata between children with IBD and healthy siblings.
6-MP, 6-mercaptopurine; TNF, tumor necrosis factor; UGI,
upper gastrointestinal.
aImmunomodulators (methotrexate, 6-mercaptopurine) were
combined with anti–tumor necrosis factor therapy in all
except 2 patients.
bGestational age was expressed as weeks from full-term.
cExclusive breastfeeding was for at least 4 months after birth.
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modeling of OTUs at the 97% sequence identity threshold,
roughly corresponding to species.28 This model best fit the
data when the cohort was divided into 2 groups that we
termed OTU types, which were detectable at a sequence
depth of 10,000 reads or more per sample (Figure 3A, and
data not shown). These OTU types did not correspond to
the 3 enterotypes reported in a genus-level analysis of
European, American, and Japanese fecal microbiota that
were differentiated by abundance of Bacteroides, Prevotella,
and Ruminococcus (Figure 3C).21 OTU type 2 was associated
strongly with IBD, particularly CD (Figure 1B). Nineteen of
the 21 families included at least 1 individual with IBD who
carried OTU type 2, indicating that the association of this
microbial community state with IBD was not a family-
specific trait. Although most healthy relatives had OTU
type 1, 10 carried OTU type 2. In PCoA plots, OTU type 1
encompassed a region with high microbial diversity
whereas OTU type 2 mapped to a lower-diversity region
(Figure 1A). The difference in microbial a diversity between
OTU types was observed in separate comparisons of CD
subjects and healthy relatives, and confirmed using phylo-
genetic diversity and the Shannon index (data not shown).
However, within the same OTU type, differences in micro-
bial diversity between CD and non-IBD did not reach
significance (Figure 1C). Hence, OTU type 2 represents a
low-diversity microbial state independent of IBD status.
Two families contained 5 of 10 of the healthy relatives with
OTU type 2, although the relationship between OTU type
and family among healthy relatives did not reach statistical
significance (Fisher exact test, P ¼ .08) (Table 2).
We then identified taxa associated with IBD status and
OTU type using DESeq2, an algorithm that uses an empiric
Bayesian approach to shrink dispersion and fits the data to
negative binomial models. At the genus level, microbial
community type was associated with shifts in the abun-
dance of 40 microbial genera compared with 21 for CD and
15 for UC (Figure 4). Similarly, far more OTUs were
differentially abundant between the 2 OTU types (752)
than between non-IBD individuals and either CD (162) or
UC (44) patients (Figure 1D and Supplementary Table 1).
Rarefaction analysis showed that the number of differen-
tially abundant microbial taxa increased with greater
sequence depth, whereas a and b diversity comparisons
were largely unaffected by sequence depth greater than
3000 (data not shown). OTU type 2 was enriched in
abundant members of the Blautia (Ruminococcus), and
Bacteroides genera and depleted in an abundant member
of the Ruminococcus genus (Figure 1E). Some OTUs,
including Veillonella dispar, Veillonella parvula, Blautia
producta, Haemophilus parainfluenzae, and multiple
Enterobacteriaceae, were associated independently with
both OTU type and CD. The CD-specific microbial signature
included increased Bifidibacterium adolescentis and
Parabacteroides distasonis and decreased F prausnitzii
and Bacteroides fragilis. OTU type 2, CD, and UC were
associated with decreased Akkermansia mucinophila
(Figures 1E and 4).
Figure 2. Microbial composition and metabolomics vary across families. (A) Box plots showing unweighted UniFrac
distances for all pairwise combinations of individuals across families or within the same family were generated in QIIME using
the function make_distance_boxplots. Lower values indicate a greater similarity of microbial communities. Increased similarity
when comparing pairs of samples within families relative to the similarity of pairs of samples from different families implies an
effect of family on microbial composition. This approach has been used in studies comparing monozygotic and dizygotic twins
to show a role for genes in regulating microbial composition.51 Statistical significance was calculated in QIIME using t tests
with 100,000 Monte Carlo simulations. (B) PCoA plot showing microbial composition divided by family (each symbol/color
combination represents 1 of the 21 families in this cohort). P value was calculated using Adonis. (C) Box plots showing root
square Jensen–Shannon divergence (distance) of the fecal metabolome for all pairwise combinations of individuals across and
within IBD groups or families. Statistical significance was calculated using t tests with 100,000 Monte Carlo simulations. (D)
PCoA plot showing metabolomics data by family.
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Independent Pediatric CD Cohort
We then investigated whether the 2 OTU types
described in this cohort could be mapped to the RISK
cohort, consisting of new-onset pediatric Crohn’s disease
patients and children presenting with gastrointestinal
symptoms but without evidence of inflammatory disease.9
We first created a random forest classifier for microbial
community type using the family cohort data. This clas-
sifier was highly accurate in 10-fold cross-validation, with
an area under the curve (AUC) of the receiver operating
characteristic curve of 0.97 (Figure 5A). The relative
contribution of OTUs to the classifier was expressed as
importance scores, which measure the loss in accuracy of
the random forest classifier when that feature is permu-
tated randomly. The OTUs that had the greatest impact onthe random forest classifier for OTU types were [Rumi-
nococcus] gnavus (increased in OTU type 2), an uniden-
tified Bacteroides (increased in OTU type 1), 2
unidentified members of the Lachnospiraceae family
(1 associated with each OTU type), and Roseburia faecis
(increased in OTU type 1), of which only R faecis was
associated independently with IBD (Figure 5B). The
classifier then was applied to stool samples in the RISK
cohort from patients (n ¼ 177) and controls (n ¼ 28) to
identify OTU types in this independent cohort. These
stool samples formed a gradient by microbial diversity
similar to that of the stool samples from the family cohort
(Figures 1A and 5C). As in the family cohort, predicted
OTU type 2 in the RISK cohort was associated with CD as
well as with lower microbial diversity irrespective of
disease status (Figure 5D and E).
Figure 3. Dirichlet multinomial mixture models support the presence of 2 OTU types and 2 metabotypes. (A and B)
The model fit is shown for the given number of (A) OTU types and (B) metabotypes estimated from Dirichlet multinomial
mixture models using the Laplace approximation. The exponent of the difference in model fit is the estimated probability
of one model over another. (C) No statistically significant difference in Bacteroides or Prevotella abundance was observed
between the 2 OTU types in our cohort. Ruminococcus was increased in OTU type 1 but this was not the exclusive driver
of OTU type because 2 individuals with OTU type 2 had greater Ruminococcus levels than all individuals with OTU type 1.
**P < .005.
Table 2.Metabotypes and OTU Types of Healthy First-
Degree Relatives Are Associated With Family
Family
OTU type Metabotype
1 2 1 2
BSD2205 2 0 2 0
BSD2780 1 0 1 0
BSD3178 2 1 1 2
BSD3205 2 0 0 2
BSD3448 0 3 0 3
BSD3486 2 0 2 0
BSD3590 2 0 1 1
BSD3724 3 0 3 0
BSD3803 2 0 1 1
BSD3888 3 0 3 0
BSD3905 3 0 2 1
BSD4031 1 1 2 0
BSD4241 4 0 2 2
BSD4257 1 2 1 2
BSD4287 2 0 1 1
BSD4343 2 1 3 0
BSD4346 2 0 2 0
BSD4352 2 0 2 0
BSD4362 4 1 5 0
BSD5304 1 1 1 1
BSD5502 3 0 3 0
Total 44 10 38 16
P value .08 .03
NOTE. Contingency tables are shown for OTU type and
metabotype of the 54 non-IBD individuals across the
21 families in this cohort. P values were calculated using
the Fisher exact test. Two families are highlighted (BSD4257,
BSD3448) that contain at least 2 individuals with
the IBD-associated OTU type and metabotype.
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We performed untargeted UPLC/ToFMS metabolomics
to further investigate the functional consequences of altered
microbial composition in our family cohort. Our pipeline
detected 4626 spectral features across 2 acquisition modes.
Differences across samples in the intensities of these spec-
tral features were visualized by PCoA. Healthy relatives and
CD patients mostly separated to opposite ends of the PCoA
space with an area of overlap between the two, although UC
patients were found in both regions (Figure 6A). Metab-
olomics signatures also varied by family (Adonis, P < 10-5),
showing that shared genetic and/or environmental factors
within families influenced the composition of the metab-
olome (Figure 2C and D). A random forests classifier was
trained on the metabolomics data to determine the
discriminative power of fecal metabolites to predict CD from
non-IBD. Differences in metabolomics profiles between CD
and non-IBD were sufficient for the classifier to have an AUC
of 0.89 in 10-fold cross-validation (Figure 6B). We then used
multivariate models to identify specific spectral features
associated with CD or UC, adjusting for covariates including
sex, anti–tumor necrosis factor therapy, Jewish ethnicity,
mode of delivery, and calprotectin. CD patients had altered
abundance of 123 spectral features whereas UC patients
showed comparatively little change: 20 spectral features, of
which 5 were shared with CD and 2 were validated as
mesalamine (a common treatment for UC in this cohort)
(Figure 6C). Hierarchical clustering of differential spectral
features in CD showed that most Crohn’s patients and a
subset of healthy individuals grouped together whereas
other non-IBD individuals had a distinct profile. CD-
associated metabolites included amino acid derivatives
(phenylethylamine and N-acetylcadaverine) and bile acids
(cholic acid, 7-ketodeoxycholic acid, chenodeoxycholic acid
sulfate, and 3-sulfodeoxycholic acid) (Figure 6D). Metabo-
lites that were increased in non-IBD individuals included a
heme degradation product (stercobilin), a glutamate
758 Jacobs et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 6derivative (acetyl-glutamic acid), and a product of steroid
catabolism (boldione).
The grouping of some non-IBD individuals with CD pa-
tients by hierarchical clustering suggested the existence of
metabotypes in this cohort analogous to the 2 OTU types.
Dirichlet multinomial mixture models supported 2 metab-
otypes (Figure 3B). PCoA plots showed separation of in-
dividuals in the cohort by metabotype and a notable overlap
of metabotype 1 with non-IBD individuals (Figures 6A and
7A). As with OTU type, metabotype was found to be corre-
lated highly with IBD status (Fisher exact test, P ¼ 1  10-6)
and also was correlated with family (P ¼ .03) (Figure 7B and
Table 2). A random forest classifier for metabotype was
trained with an AUC of 1.0, indicative of the robust difference
between the 2 metabotypes (Figure 7C). We then used
multivariate models that included metabotype to identify
IBD-associated spectral features independent of metabotype
(Figure 7D and Supplementary Data File 2). CD and UC were
found to have a limited metabolic signature with only 9 dif-
ferential features each, whereas metabotype was associated
with 516 spectral features. This suggested that metabotype
accounted for much of the variation in the metabolome that
had been attributed to disease status without considering
metabotype. Metabotype 2 was characterized by increased
levels of the same bile acids and amino acid derivatives pre-
viously attributed to CD as well as taurine, tryptophan, serinyl
tryptophan, and an omega-6 fatty acid (adrenic acid)
(Figure 7E). Metabotype 1 had increased levels of steroid
hormones (estradiol, androstenedione, and boldione), prod-
ucts of heme catabolism (stercobilin and mesobilirubinogen),
azaleic acid, and acetyl-glutamic acid. Estradiol and andro-
stenedione abundancewashigher in females than inmales, but
in both sexes increased levels of these hormones were seen in
metabotype 1 (data not shown).OTU Type and Metabotype Are Highly Correlated
The similarity between OTU types and metabotypes
suggested a functional relationship between the microbiome
and metabolome. This was visualized using Procrustes to
rotate and rescale the metabolomics PCoA data to allow it to
be superimposed onto the microbiome PCoA data. The 2
data sets showed a high degree of concordance that was
statistically significant in Monte Carlo simulations with a P
value less than .0001 (Figure 8A). Superimposed micro-
biome and metabolomics data were separated not only by
IBD status but also by OTU type and metabotype. Contin-
gency table analysis showed a strong association between
OTU types and metabotypes (Fisher exact test, P ¼ 3  10-8)
that was present even when considering only the healthy
relatives in this cohort (P ¼ .004) (Figure 8B).
We next sought to investigate the individual microbe–
metabolite associations that underpin the relationship be-
tween microbial community type and metabotype. An
inter’omic network was constructed using all OTU-type–
associated microbes and metabotype-associated metabolites
with an importance score of 2 (ie, 2 standard deviations above
having no effect on classification) (Figure 8C). Edges in this
network represented statistically significant correlationsbetween 2 microbes, 2 metabolites, or a microbe and
metabolite after adjustment for sex, Jewish ancestry, current
anti–tumor necrosis factor therapy, mode of delivery, family
group, IBD diagnosis, and OTU type/metabotype. Inter’omic
degree centrality—the number of edges to nodes of the
opposite data type (ie, microbe–metabolite correlations)—
was calculated to highlight microbes associated with the
largest number of metabolites and vice versa. Three metab-
olites were found to have a high inter’omic centrality,
including adrenic acid and 2 unidentified metabolites, as a
result of association with a group of co-correlated Blautia
OTUs, [Ruminococcus] gnavus, [Eubacterium] dolichum, Veil-
lonella dispar, and Holdemania. The metabotype 2 associated
bile acids were highly co-correlated in the network. Two bile
acids, 7-sulfocholic acid and chenodeoxycholic acid sulfate,
were associated with a Lachnospiraceae OTU enriched in OTU
type 2.Increased Incidence of Elevated Fecal Calprotectin
in Healthy First-Degree Relatives With the
IBD-Associated Microbial Community Type
We then evaluated the relative association of OTU type
and metabotype with IBD in multivariate logistic regression
models. OTU type and metabotype each had a statistically
significant correlation with IBD in univariate logistic
regression with odds ratios of 13.2 and 8.3, respectively,
although only OTU type retained significance in multivariate
logistic regression models that included OTU type, metab-
otype, parent/child status, and Jewish ethnicity (Figure 9A).
We investigated whether OTU type was associated with an
increased risk of subclinical intestinal inflammation as evi-
denced by increased fecal calprotectin.35 The majority of
samples had calprotectin levels below the limit of detection.
We selected 100 mg/g as a cut-off value for increased fecal
calprotectin based on a meta-analysis of the use of calpro-
tectin to differentiate IBD from healthy controls or irritable
bowel syndrome.36 Only 3 of 44 healthy relatives (7%) with
OTU type 1 and 3 of 10 relatives (30%) with OTU type 2 had
increased calprotectin levels (Figure 9B). This corresponded
to an odds ratio of 5.9 (confidence interval, 0.9–37.9) for the
association of OTU type 2 with increased calprotectin level,
with a P value of .05. Five of 21 healthy siblings carried the
IBD-associated OTU type, of whom 4 also had the
IBD-associated metabotype (Figure 9C).Discussion
Although there has been much focus on the microbiota
associated with disease activity in IBD, a separate and
experimentally challenging concept is the possibility of
distinctive basal states of the intestinal microbiome that
confer disease susceptibility. We found that variation in the
microbiome and metabolome among disease-quiescent IBD
patients and their first-degree relatives can be represented
by 2 intestinal OTU types and metabotypes. The existence of
an IBD-associated OTU type and metabotype in healthy rel-
atives suggests that dysbiosis with its associated metabolic
products may be a pre-existing trait that precedes the
Figure 4. Microbial
genera associated with
IBD status and OTU type.
Fold-change is shown for
genera associated with CD
(vs non-IBD), UC (vs non-
IBD), or OTU type (2 vs 1)
with q less than .05 in
multivariate DESeq2
models including sex,
Jewish ancestry, current
anti–tumor necrosis factor
therapy, mode of delivery,
family group, IBD diag-
nosis, and OTU type as
covariates. Some taxa
represent unclassified
members of the indicated
family (f) or order (o).
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Figure 5. Microbial community types were predicted in an independent cohort of pediatric CD patients using a random
forest classifier. (A) A classifier was created to predict OTU type in the family cohort using 57 OTUs that were differentially
abundant in DESeq2 models and were present in at least 30% of samples. The receiver operating characteristic curve of this
classifier based on 10-fold cross-validation is shown. (B) Log2 FC between OTU types 2 and 1 in the family cohort for OTUs
included in the random forest classifier. Size is proportional to the importance score of the OTU in the classifier, which
measures the loss in accuracy of the classifier when the OTU is permutated randomly. (C) PCoA plots visualizing microbial
composition in the RISK cohort of pediatric CD patients and controls with gastrointestinal symptoms but no evidence of
inflammatory disease. Samples are colored by IBD status, Chao1, or OTU type predicted from the classifier shown in panel A.
P values were calculated using Adonis. (D) Contingency table of IBD status by predicted OTU type in the RISK cohort. P value
was calculated using the Fisher exact test. (E) Chao1 was determined by IBD status and predicted OTU type in the RISK
cohort. P values were calculated using the Mann–Whitney U test. ***P < .0001.
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IBD-associated OTU type included multiple OTUs identified
as Enterobacteriaceae and 2 putatively identified as Pre-
votella copri. This parallels studies of Toll-like receptor 5
knockout mice and NLRP6 inflammasome knockout mice
showing that colitis susceptibility was associated with
blooms of Enterobacteriaceae and Prevotellaceae, respec-
tively.5,37 Although unaffected family members were not
evaluated endoscopically for IBD, the study design included
clinical assessment at recruitment and periodic monitoring
for acquisition of clinical disease. Healthy individualswith theIBD-associated OTU type and metabotype were found pre-
dominantly in several families. Such states may have arisen
owing to shared founder effects, dietary factors, and genetic
variants between patients and some of their family members
that influence host–microbiome homeostasis.11,12,38
The metabotypes identified in this cohort may be driven
by shifts in bacterial metabolism of host-derived factors
such as bile acids due to altered microbial community
structure, explaining the close correlation of metabotype
with OTU type. Metabotype 2 showed increased levels of
cholic acid (a primary bile acid) and a sulfated derivative
Figure 6. Metabolomic features of CD also were seen in a subset of healthy relatives. (A) PCoA plots were used to
visualize differences in metabolomics profiles across samples as measured by the square root of the Jensen–Shannon
divergence. Dots represent fecal samples, colored by IBD status. Dot size corresponds to fecal calprotectin level in the lower
panel. P values were calculated using Adonis. Separate calculations were made for the whole cohort and for just the CD
subset because increased calprotectin was seen primarily in a subset of CD. (B) A random forest classifier was created to
distinguish CD from non-IBD using fecal metabolomics profiles. The receiver operating characteristic curve of this classifier
based on 10-fold cross-validation is shown. (C) Venn diagram of the differential spectral features for CD or UC vs non-IBD in
multivariate DESeq2 models including sex, Jewish ancestry, current anti–tumor necrosis factor therapy, mode of delivery,
family group, and IBD diagnosis as covariates. The heat map shows intensity values for the 123 spectral features with dif-
ferential abundance in CD vs non-IBD. Intensity is represented on a color scale spanning 3 standard deviations above and
below the mean across all samples. Samples and spectral features were clustered hierarchically by Pearson correlation
coefficient with the average linkage method. IBD status of samples is indicated by colored boxes above the heat map. (D)
Spectral features differentially abundant in CD or UC (as summarized in the Venn diagram in panel C) are shown, arranged by
retention time. Effect size is represented as the log2 FC in CD or UC compared with non-IBD in multivariate DESeq2 models.
Features associated with both CD and UC are plotted by the log2 FC in CD vs non-IBD. Size is proportional to the importance
score of the feature in the random forest classifier for CD. The names of validated metabolites are shown. Lower panel: the
density of detected spectral features by retention time on the UPLC column.
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sulfated derivatives of the other primary bile acid, cheno-
deoxycholic acid. These findings parallel a study that re-
ported increased conjugated and sulfated bile acids in the
feces of CD patients attributed to reduced capacity of the CDmicrobiome to deconjugate and desulfate bile acids.39 The
increased levels of cholic acid may reflect reduced conver-
sion to other bile acid metabolites. The other validated bile
acid associated with metabotype 2, 7-ketodeoxycholic acid,
has not been reported previously to be increased in CD or
Figure 7. Fecal metabotypes are associated with IBD status. (A) PCoA plots of the metabolomics profile of fecal samples
colored by metabotype (determined using Dirichlet multinomial mixture models). (B) Contingency table of IBD status by
metabotype. The P value was calculated using the Fisher exact test. (C) A random forest classifier was created to predict
metabotype. The receiver operating characteristic (ROC) curve of this classifier based on 10-fold cross-validation is shown. (D)
Venn diagram showing the number of differential spectral features for metabotypes 2 vs 1, CD vs non-IBD, and UC vs non-IBD
in multivariate DESeq2 models including sex, Jewish ancestry, current anti–tumor necrosis factor therapy, mode of delivery,
family group, IBD diagnosis, and metabotype as covariates. (E) Metabotype-associated spectral features are shown, plotted
by retention time. Effect size is represented as the log2 FC of metabotypes 2 vs 1 in multivariate DESeq2 models. Size is
proportional to the importance score of the feature in the random forest classifier for metabotype. The names of validated
metabolites are shown, color-coded by metabolite category.
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deoxycholic acid (a secondary bile acid).40,41 The bile acid
shifts in metabotype 2 likely are relevant to the develop-
ment of dysbiosis and IBD given the considerable evidence
that bile acid signaling through farnesoid X receptor and
TGR5 is critical for maintaining the epithelial barrier and
promoting antibacterial defenses.42–44 There also are recent
data indicating that bile acids including cholic acid can
induce enterochromaffin cells to secrete serotonin, a
neurotransmitter shown to promote experimental coli-
tis.45,46 This could be potentiated by the increased levels in
metabotype 2 of tryptophan, an essential amino acid that is
the precursor to serotonin and that also can be metabolizedby microbes into immunomodulatory metabolites including
kynurenines and an aryl hydrocarbon receptor ligand,
indole-3-aldehyde.47,48 The possible causal link between
OTU type and metabotype, with its associated alteration of
bile acid metabolism, warrants mechanistic investigation in
models of germ-free mice colonized with feces of each OTU
type/metabotype. Interestingly, 19 of 90 subjects had
discordant OTU type and metabotype, suggesting that other
factors besides the microbiome such as diet also could
influence the metabolome.49
A strength of this study was that its central finding (a
disease-related microbial community type detectable in
healthy subjects) also was observed in the RISK cohort,
Figure 8. Microbe–metabolite interactions between the IBD-associated microbial community type and metabotype. (A)
The PCoA plot for the metabolome (visualized in Figure 6A) was rotated and rescaled using Procrustes, then superimposed on
the PCoA plot for the microbiome (visualized in Figure 1A). Points represent 16S rRNA and UPLC/ToFMS data, color-coded by
IBD status, OTU type, or metabotype. Each line connects the microbial and metabolomics data from one individual. (B)
Contingency table of OTU type and metabotype for the full cohort and only non-IBD individuals. P values were calculated
using the Fisher exact test. (C) An inter’omic network was constructed with nodes representing OTU-type–associated
microbes and metabotype-associated spectral features with an importance score greater than 2 in random forest classifiers.
Microbe (circle) and metabolite (triangle) nodes are outlined in red if they are decreased in OTU type 2 or metabotype 2,
respectively. Node size reflects inter’omic degree centrality—the number of connections to nodes of the opposite data type (ie,
microbe–metabolite pairs). Edges represent statistically significant correlations (q < 0.05) between microbe–microbe,
metabolite–metabolite, or microbe–metabolite pairs. These correlations were made using residuals from multivariate DESeq2
models adjusting for sex, Jewish ancestry, current anti–tumor necrosis factor therapy, mode of delivery, family group, IBD
diagnosis, and OTU type/metabotype. This approach highlights correlations that cannot be explained by these factors.
Selected microbes and metabolites are indicated by fill color, numbers, or letters.
November 2016 IBD-Associated Microbial/Metabolomics State 763which consisted of more than 200 unrelated pediatric
patients and controls from a large network of pediatric
gastroenterology clinics across North America.9 At least 2
prior publications have reported that IBD patients cluster
into 2 groups by microbiome composition.6,10 In an early
Sanger sequencing study of ileal and colonic surgical spec-
imens, OTU presence/absence was used to group non-IBD
subjects and the majority of IBD patients into 1 cluster
while a subset of IBD patients formed a second cluster with
increased Proteobacteria and Actinobacteria OTUs. The
second cluster was associated with abscess, suggesting that
it was driven by CD patients with penetrating disease. A
second study used genus level fecal microbiome data to
group CD patients with active disease into near and far
clusters to reflect their closeness to the microbiome of
healthy controls.10 The far cluster was characterized by
lower microbial diversity and differential abundance of 30
genera, of which 7 had concordant differences between the2 OTU types defined here (Figure 4). The present study
builds on these observations by showing that microbial
community types found in IBD patients also are present in
healthy relatives. Furthermore, microbial community types
were associated with metabolomics profiles and subclinical
intestinal inflammation, indicating functional relevance of
this community structure. A limitation of this study was the
small number of high-risk families and their lack of ethnic
and racial diversity. However, we are not aware of other
published family based or longitudinal cohorts analyzed for
microbiome and metabolites. Their availability will be
important to validate the present observations and refine
them in broader populations that include other racial or
ethnic groups.
The microbial state defined by OTU type 2 was associ-
ated not just with diagnosed IBD but also with a potential
subclinical disease state defined by increased fecal calpro-
tectin in healthy first-degree relatives. Nevertheless, most
Figure 9. Healthy first-degree relatives with the IBD-associated microbial community type are at higher risk for
increased fecal calprotectin. (A) Unadjusted odds ratios (ORs) and 95% confidence intervals were calculated for IBD risk
using univariate logistic regression. Adjusted ORs were obtained from a multivariate logistic regression model incorporating
OTU type, metabotype, parent/child status, and Jewish ethnicity. (B) Dot plot showing fecal calprotectin in the 54 healthy first-
degree relatives, stratified by OTU type. The lowest 2 rows of dots represent samples below or near the limit of detection of
15.6 mg/g. The P value was calculated from univariate logistic regression for increased calprotectin level (cut-off value is
indicated by the dashed line). (C) Pedigrees are shown for 5 families with healthy children who carry an IBD-associated OTU
type. Two of these children had an increased fecal calprotectin level.
764 Jacobs et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 6individuals with the IBD-associated OTU type and metab-
otype had normal calprotectin level. This suggests that these
microbial changes are not simply the result of subclinical
inflammation, although we cannot rule out that OTU type
and metabotype are more sensitive biomarkers for low-
grade inflammation than calprotectin. We speculate that
healthy individuals with an IBD-associated microbial com-
munity type and metabotype have a predisease state that
increases the risk for the future development of both sub-
clinical and overt IBD. Validating this interpretation will
require prospective longitudinal studies to assess the inci-
dence of IBD in individuals stratified by OTU type, metab-
otype, and calprotectin, and to assess the stability of OTU
types and metabotypes across time and diet. Analytically, it
also will require bioinformatically fastidious methods to
refine and simplify the definition of microbial community
types that robustly are preserved between independent
cohorts and data sets, and illuminate and resolve the
methodologic and ecologic questions raised by prior studies
of intestinal microbiome clustering.50 Future cohort studies
would need to incorporate known genetic and epidemio-
logic risk factors to determine the risk for IBD attributable
to OTU type and metabotype after adjusting for these other
factors. In addition, studies of germ-free mice colonized with
feces from healthy relatives stratified by OTU type and
metabotype are warranted to investigate whether thesemicrobial states influence susceptibility to experimental
models of IBD. If validated, prospective identification of
healthy individuals with a high-risk microbiome/metab-
olome creates the opportunity to prevent disease develop-
ment by targeting the dysbiosis and/or its metabolic
consequences in the intestine.References
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